Financial & Tax Architects LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 8.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 30,647 shares of the company’s stock after buying an additional 2,378 shares during the quarter. Financial & Tax Architects LLC’s holdings in Johnson & Johnson were worth $4,750,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. Veracity Capital LLC grew its holdings in Johnson & Johnson by 1.2% in the fourth quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock valued at $888,000 after purchasing an additional 59 shares during the last quarter. LCM Capital Management Inc grew its holdings in Johnson & Johnson by 0.7% in the fourth quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock valued at $1,667,000 after purchasing an additional 61 shares during the last quarter. Arbor Investment Advisors LLC grew its holdings in Johnson & Johnson by 2.3% in the fourth quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock valued at $476,000 after purchasing an additional 61 shares during the last quarter. Sierra Capital LLC grew its holdings in Johnson & Johnson by 0.6% in the fourth quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock valued at $1,773,000 after purchasing an additional 61 shares during the last quarter. Finally, Retirement Planning Group grew its holdings in Johnson & Johnson by 1.8% in the fourth quarter. Retirement Planning Group now owns 3,437 shares of the company’s stock valued at $607,000 after purchasing an additional 62 shares during the last quarter. 67.57% of the stock is owned by institutional investors and hedge funds.
Johnson & Johnson Stock Performance
Johnson & Johnson stock opened at $170.19 on Friday. The stock’s 50-day moving average is $160.37 and its 200-day moving average is $161.39. The company has a market cap of $442.28 billion, a price-to-earnings ratio of 35.60, a price-to-earnings-growth ratio of 2.72 and a beta of 0.55. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $181.04.
Johnson & Johnson Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be paid a $1.19 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.80%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 99.58%.
Insider Activity
In other news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares in the company, valued at $10,549,440. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.20% of the company’s stock.
Analyst Ratings Changes
Several research firms have weighed in on JNJ. Raymond James lowered their target price on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a report on Wednesday, April 19th. Stifel Nicolaus increased their price objective on Johnson & Johnson from $165.00 to $175.00 in a research note on Friday. StockNews.com initiated coverage on Johnson & Johnson in a research note on Thursday, May 18th. They set a “strong-buy” rating on the stock. Atlantic Securities decreased their price objective on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 19th. Finally, TheStreet lowered Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Eight investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Hold” and a consensus price target of $171.40.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- MarketBeat Week in Review – 7/17 – 7/21
- U.S. Bancorp Shares Rally As Analysts Get Bullish After Q2 Report
- AutoNation Beats Earnings Expectations, Stock Down?
- American Express Hiccups After Earnings, Time To Buy?
- ISRG Stock Sinks After Strong Earnings: Is the Growth Priced In?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
